To evaluate the neovascular age-related macular degeneration (nAMD) in patients who were morphologically poor responders to intravitreal ranibizumab (IVR) treatment using indocyanine green angiography ...
BARCELONA, Spain — Patients who receive a diagnosis of neovascular age-related macular degeneration (nAMD) from their primary care clinician may be less likely to adhere to treatment than those who ...
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end 1 Over 60% of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Innovative drug classes and advanced delivery systems ...
New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained ...
STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback